Description and Brand Names
Drug information provided by: IBM Micromedex
US Brand Name
- Zinbryta
Descriptions
Daclizumab injection is used to treat the relapsing forms of multiple sclerosis (MS). This medicine will not cure MS, but it may slow some of the disabling effects and decrease the number of relapses of the disease. It should only be used when other medicines to treat MS did not work well.
This medicine was available only under a restricted distribution program called the Zinbryta® REMS (Risk Evaluation and Mitigation Strategy) Program.
Daclizumab was voluntarily withdrawn from the worldwide market on March 2, 2018 due to safety concerns.
Portions of this document last updated: Feb. 01, 2020
Copyright © 2020 IBM Watson Health. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.